ProCE Banner Activity

Overview of Immunotherapy Options for Treatment-Naive ES-SCLC

Slideset Download
Download this brief slideset for a review of the latest clinical data informing optimal use of immunotherapy for treatment-naive ES-SCLC.

Released: December 01, 2020

Expiration: November 30, 2021

No longer available for credit.

Share

Faculty

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania